Cargando…

Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes

Cancers harboring mutations in the Kirsten rat sarcoma homolog (KRAS) gene have been associated with poor prognosis and lack of targeted therapies. KRAS mutations occur in approximately one in four patients diagnosed with non-small cell lung cancer (NSCLC) with KRAS G12C mutations harbored at approx...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palma, Gabriela, Khurshid, Faisal, Lu, Kevin, Woodward, Brian, Husain, Hatim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630042/ https://www.ncbi.nlm.nih.gov/pubmed/34845311 http://dx.doi.org/10.1038/s41698-021-00237-5

Ejemplares similares

Intracranial responses with selective KRAS-G12C inhibitors in non-small cell lung cancer
por: Lu, Kevin, et al.
Publicado: (2023)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
por: Gillson, Josef, et al.
Publicado: (2020)

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
por: Khan, Husain Yar, et al.
Publicado: (2022)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers
por: Khan, Husain Yar, et al.
Publicado: (2023)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer
por: Blaquier, Juan Bautista, et al.
Publicado: (2021)

Modeling receptor flexibility in the structure-based design of KRAS(G12C) inhibitors
por: Zhu, Kai, et al.
Publicado: (2022)

The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2021)

The Prevalence and Concurrent Pathogenic Mutations of KRAS(G12C) in Northeast Chinese Non-small-cell Lung Cancer Patients
por: Liu, Yan, et al.
Publicado: (2021)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer
por: Kulkarni, Prakash, et al.
Publicado: (2023)

Landscape of KRAS(G12C), Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
por: Salem, Mohamed E., et al.
Publicado: (2022)

Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors
por: Stites, Edward C., et al.
Publicado: (2018)

Corrigendum: The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2022)

AZD4625 is a Potent and Selective Inhibitor of KRAS(G12C)
por: Chakraborty, Atanu, et al.
Publicado: (2022)

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
por: Bannoura, Sahar F., et al.
Publicado: (2022)

Immune modulatory effects of oncogenic KRAS in cancer
por: Hamarsheh, Shaima’a, et al.
Publicado: (2020)

Efficacy of a Small-Molecule Inhibitor of Kras(G12D) in Immunocompetent Models of Pancreatic Cancer
por: Kemp, Samantha B., et al.
Publicado: (2023)

Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer
por: Feng, Juanjuan, et al.
Publicado: (2023)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS(G12C) inhibitors
por: Feng, Siyu, et al.
Publicado: (2022)

KRasG12C inhibitors in clinical trials: a short historical perspective
por: Goebel, Lisa, et al.
Publicado: (2020)

The path to the clinic: a comprehensive review on direct KRAS(G12C) inhibitors
por: Kwan, Albert K., et al.
Publicado: (2022)

Direct GDP-KRAS(G12C) inhibitors and mechanisms of resistance: the tip of the iceberg
por: Rosen, Joshua C., et al.
Publicado: (2023)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations
por: Lanman, Brian A., et al.
Publicado: (2022)

KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
por: Mao, Zhongwei, et al.
Publicado: (2022)

The current landscape of using direct inhibitors to target KRAS(G12C)-mutated NSCLC
por: Batrash, Firas, et al.
Publicado: (2023)

An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
por: von Karstedt, Silvia, et al.
Publicado: (2020)

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
por: Mohanty, Atish, et al.
Publicado: (2023)

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
por: Notario, Lucía, et al.
Publicado: (2023)

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS(G12C) Inhibitor
por: Bröker, Joachim, et al.
Publicado: (2022)

Sustainability and international chemistry collaboration
por: Welton, Tom
Publicado: (2021)

Social Media for Chemistry Scholars
por: Ciriminna, Rosaria, et al.
Publicado: (2023)

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
por: Vaclova, Tereza, et al.
Publicado: (2022)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5fijnqkogcbc1tsvq24r69m1o2